Amounts attributable to equity method investees are as follows:
| | | | | | | | | | | | | | | | | | | (In millions) | 2024 | | 2023 | | 2022 | Sales to equity method investees included in Product sales | $ | 2,956 | | | $ | 2,920 | | | $ | 2,845 | | Purchases from equity method investees included in Cost of products sold | $ | 237 | | | $ | 214 | | | $ | 331 | |
The Company had receivables from and payables to equity method investees as follows:
| | | | | | | | | | | | | (In millions) | 2024 | | 2023 | Receivables from equity method investees included in Accounts receivable, net | $ | 363 | | | $ | 231 | | Payables to equity method investees included in Accounts payable | $ | 32 | | | $ | 44 | |
Summarized unaudited financial information for equity method investments is as follows:
| | | | | | | | | | | | | | | (In millions) | 2024 | | 2023 | | Current assets | $ | 12,823 | | | $ | 11,432 | | | Non-current assets | 2,396 | | | 1,834 | | | Total assets | 15,219 | | | 13,266 | | | | | | | Current liabilities | (11,053) | | | (9,296) | | | Non-current liabilities | (210) | | | (190) | | | Total liabilities | (11,263) | | | (9,486) | | | Total net equity of investees | $ | 3,956 | | | $ | 3,780 | |
| | | | | | | | | | | | | | | | | | | | | (In millions) | 2024 | | 2023 | | 2022 | | Net sales | $ | 17,567 | | | $ | 16,180 | | | $ | 11,524 | | | Gross profit | $ | 3,063 | | | $ | 2,862 | | | $ | 2,274 | | | Income from continuing operations | $ | 700 | | | $ | 655 | | | $ | 757 | | | Net earnings (loss) | $ | 700 | | | $ | 655 | | | $ | 757 | |
|